Selling, General, and Administrative Costs: BeiGene, Ltd. vs Agios Pharmaceuticals, Inc.

Biotech Giants' SG&A Costs: A Decade of Change

__timestampAgios Pharmaceuticals, Inc.BeiGene, Ltd.
Wednesday, January 1, 2014191200006930000
Thursday, January 1, 2015359920007311000
Friday, January 1, 20165071400020097000
Sunday, January 1, 20177112400062602000
Monday, January 1, 2018114145000195385000
Tuesday, January 1, 2019132034000388249000
Wednesday, January 1, 2020149070000600176000
Friday, January 1, 2021121445000990123000
Saturday, January 1, 20221216730001277852000
Sunday, January 1, 20231199030001504501000
Monday, January 1, 2024156784000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of BeiGene, Ltd. and Agios Pharmaceuticals, Inc. from 2014 to 2023. Over this period, BeiGene's SG&A expenses skyrocketed by over 21,000%, reflecting its aggressive expansion strategy. In contrast, Agios Pharmaceuticals saw a more modest increase of around 525%, indicating a steadier growth approach.

Key Insights

  • 2014-2017: Agios led with higher SG&A costs, but BeiGene's expenses began to catch up.
  • 2018-2023: BeiGene surpassed Agios, peaking in 2023 with expenses nearly 13 times higher than Agios.

This data highlights the contrasting strategies of these two companies, offering a fascinating glimpse into their operational priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025